# HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC

> **NCT07591805** · PHASE2 · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 49 (estimated)

## Conditions studied

- Upper Urinary Tract Urothelial Carcinoma

## Interventions

- **DRUG:** Drug: Disitamab Vedotin

## Key facts

- **NCT ID:** NCT07591805
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-16
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07591805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07591805, "HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07591805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*